ReviewCurrent topics in microbiology and immunology2012
Control of ADAR1 editing of hepatitis delta virus RNAs.
Review in Current topics in microbiology and immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Comprehensive Analysis of Mutations in the Hepatitis Delta Virus Genome Based on Full-Length Sequencing in Individuals Infected with Genotype 3 in Brazil.Archives of virology · 2026Article
- Hepatitis D Virus: Enigmas and Gaps of Knowledge.Viruses · 2026Review
- A replication-competent deltavirus from the marsupial fat-tailed dunnartThe Journal of general virology · 2026Article
- Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment.Journal of virology · 2025Article
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- ADARs: pleiotropy in function, versatility in application.Nucleic acids research · 2025Review
- Proteins and peptides as antigen candidates for the immunodiagnosis of hepatitis D.Amino acids · 2025Review
- Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients.Biomedicines · 2025Article
- Article
- Article
- Article
- Diagnosis of HDV: From virology to non-invasive markers of fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2023Review
- Hepatitis Delta Infection: A Clinical Review.Seminars in liver disease · 2023Review
- Host-mediated RNA editing in viruses.Biology direct · 2023Review
- Medical Advances in Hepatitis D Therapy: Molecular Targets.International journal of molecular sciences · 2022Review
- Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.Expert opinion on investigational drugs · 2022Review
- Review
- The role of RNA editing enzyme ADAR1 in human disease.Wiley interdisciplinary reviews. RNA · 2022Review
- Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Hepatitis delta virus (HDV) uses ADAR1 editing of the viral antigenome RNA to switch from viral RNA replication to packaging. At early times in the replication cycle, the virus produces the protein HDAg-S, which is required for RNA synthesis; at later times, as result of editing at the amber/W site, the virus produces HDAg-L, which is required for packaging, but inhibits further RNA synthesis as levels increase. Control of editing during the replication cycle is essential for the virus and is multifaceted. Both the rate at which amber/W site editing occurs and the ultimate amount of editing are restricted; moreover, despite the nearly double stranded character of the viral RNA, efficient editing is restricted to the amber/W site. The mechanisms used by the virus for controlling editing operate at several levels, and range from molecular interactions to procedural. They include the placement of editing in the HDV replication cycle, RNA structural dynamics, and interactions of both ADAR1 and HDAg with specific structural features of the RNA. That HDV genotypes 1 and 3 use different RNA structural features for editing and control the process in ways related to these features underscores the critical roles of editing and its control in HDV replication. This review will cover the mechanisms of editing at the amber/W site and the means by which the virus controls it in these two genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.